The rapidly changing global pharmaceutical landscape reached another milestone yesterday, as Takeda Pharmaceutical Co completed its US$62 billion acquisition of Shire PLC.
Takeda’s purchase was the world’s biggest announced acquisition of last year, transforming the 237-year-old Japanese company into a top 10 drugmaker with lucrative therapies for rare diseases and a sizable footprint in the US.
It is part of a larger shift in the industry as drugmakers scramble to consolidate, seeking to bulk up to survive increasing pressure from stricter regulations on drug prices and looming patent expirations.
Already this year, the Takeda deal has been trumped in size by Bristol-Myers Squibb Co’s US$74 billion agreement last week to buy Celgene Corp.
Here is how the supersized Takeda is to look in the increasingly evolving pharmaceutical landscape:
Takeda and Shire’s combined revenue catapult it into the ranks of the global pharmaceutical majors — the first Japanese company to reach the top 10.
The new Takeda would have ranked No. 9 among the biggest drugmakers by revenue, but Bristol-Myers’ deal with Celgene, if it succeeds, would push it down one notch.
The company would also hold a unique position in being a big pharmaceutical company with a focus on rare diseases acquired from Shire’s portfolio.
One of the key drivers for the acquisition was to gain further exposure to the US, the world’s most profitable drug market. Japan has not become a dependable source for growth because of a shrinking population and regulatory pressure that has pushed down drug prices nearly every year.
Although the US also poses a drug-pricing risk, it is one most pharma giants are willing to take for the revenue stream.
Takeda would contribute further to the dealmaking frenzy, thanks to the heavy debt load it has taken on.
The company has laid out a scenario of a potential US$10 billion in divestments in an effort to deleverage. Investors should expect asset sales this year, chief executive officer Christophe Weber said on Monday.
The company is looking to divest non-core businesses outside Japan where the company is not an industry leader and does not have critical mass in the market.
Takeda’s debt load was the issue that drew the biggest fire from critics of the deal, and caused S&P Global Ratings to downgrade the drugmaker yesterday, saying that the company is unlikely to recover quickly from worsening financial ratios. Moody’s Investors Service lowered its rating last month.
Net borrowings would more than double to nearly five times earnings after it takes on about US$30 billion in debt to acquire Shire, plus the debt on that company’s books. That is compared with an industry average multiple of about one.
The company has said it intends to deleverage to a debt ratio multiple of about two within five years.
Among the rows of vibrators, rubber torsos and leather harnesses at a Chinese sex toys exhibition in Shanghai this weekend, the beginnings of an artificial intelligence (AI)-driven shift in the industry quietly pulsed. China manufactures about 70 percent of the world’s sex toys, most of it the “hardware” on display at the fair — whether that be technicolor tentacled dildos or hyper-realistic personalized silicone dolls. Yet smart toys have been rising in popularity for some time. Many major European and US brands already offer tech-enhanced products that can enable long-distance love, monitor well-being and even bring people one step closer to
Malaysia’s leader yesterday announced plans to build a massive semiconductor design park, aiming to boost the Southeast Asian nation’s role in the global chip industry. A prominent player in the semiconductor industry for decades, Malaysia accounts for an estimated 13 percent of global back-end manufacturing, according to German tech giant Bosch. Now it wants to go beyond production and emerge as a chip design powerhouse too, Malaysian Prime Minister Anwar Ibrahim said. “I am pleased to announce the largest IC (integrated circuit) Design Park in Southeast Asia, that will house world-class anchor tenants and collaborate with global companies such as Arm [Holdings PLC],”
Sales in the retail, and food and beverage sectors last month continued to rise, increasing 0.7 percent and 13.6 percent respectively from a year earlier, setting record highs for the month of March, the Ministry of Economic Affairs said yesterday. Sales in the wholesale sector also grew last month by 4.6 annually, mainly due to the business opportunities for emerging applications related to artificial intelligence (AI) and high-performance computing technologies, the ministry said in a report. The ministry forecast that retail, and food and beverage sales this month would retain their growth momentum as the former would benefit from Tomb Sweeping Day
Thousands of parents in Singapore are furious after a Cordlife Group Ltd (康盛人生集團), a major operator of cord blood banks in Asia, irreparably damaged their children’s samples through improper handling, with some now pursuing legal action. The ongoing case, one of the worst to hit the largely untested industry, has renewed concerns over companies marketing themselves to anxious parents with mostly unproven assurances. This has implications across the region, given Cordlife’s operations in Hong Kong, Macau, Indonesia, the Philippines and India. The parents paid for years to have their infants’ cord blood stored, with the understanding that the stem cells they contained